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Abstract. Epigenetic mechanisms such as histone-acetylation have been implicated with learning and memory and are believed
to contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD). Histone-deacetylase (HDAC)
inhibitors were shown to exhibit neuroprotective and neurodegenerative properties in AD animal models, and targeting HDACs
appears to be a promising therapeutic strategy for brain diseases. The role of the distinct HDAC proteins in the adult brain is,
however, not well understood and so far only pan-HDAC inhibitors have been tested in preclinical settings. Understanding the
role of individual HDACs in cognition and AD pathogenesis is therefore vital to develop more selective HDAC inhibitors for
the treatment of AD. In this study we investigated the role of HDAC5 in memory function and AD pathogenesis. We show that
loss of HDAC5 impairs memory function but has little impact on pathogenesis in a mouse model for amyloid pathology. Our
data reveals a novel role of HDAC5 in memory consolidation and shows that future approaches to develop more selective HDAC
inhibitors for the treatment of AD should avoid targeting HDAC5.
Keywords: Alzheimer’s disease, amyloid pathology, epigenetics, HDAC inhibitors, histone deacetylases, learning and memory,
neurodegenerative diseases
INTRODUCTION
Epigenetic mechanisms, such as DNA methyla-
tion and covalent histone modifications, govern gene
expression in a manner that is independent of the
DNA-blueprint [1]. This can provide an opportunity
to elucidate gene-environment interactions in com-
plex diseases such as Alzheimer’s disease (AD) that
are a burden for our modern society with a continued
extension of life expectancy [2, 3]. The precise molec-
ular mechanisms underlying this age-related cognitive
decline observed in AD is still not well understood.
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Histone-deacetylase (HDAC) proteins act in concert
with histone acetyltransferases and remove the acetyl
groups from histone and non-histone proteins [4]. The
human and rodent genome encodes 11 HDAC pro-
teins that are classified in four families HDAC I-IV:
class I (HDAC 1-3, HDAC8), class IIa (HDAC 4, 5,
7 and 9), class IIb (HDAC 6 and 10), and class IV
(HDAC 11). Previous studies demonstrated that pan-
HDAC inhibitors such as sodium butyrate, trichostatin
A, suberoylanilide hydroxamic acid, or sodium phenyl-
butyrate could be a possible therapeutic approach to
treat age-associated dementias such as AD [2, 5–12]
even at advanced states of disease progression [13].
Which of the 11 HDAC proteins is most important
for the beneficial effect of pan-HDAC inhibitors is cur-
rently not well understood. While recent data support
the view that HDAC2, a class I HDAC, is a restraint of
memory function [14] and implicated with AD pathol-
ogy [15] possibly via the regulation of histone 4 lysine
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12 acetylation mediated gene-expression [8], the role
of class II HDACs in AD has not been explored in
detail.
Thus, we decided to investigate the role of HDAC5,
a class II HDAC, that can shuttle between the nucleus
and the cytosol and deacetylates MEF2 [16], which
is essential for synaptic plasticity. Moreover, HDAC5
has been associated previously with behavioral adap-
tations to emotional stimuli such as cocaine addiction
[17–19]. Thus, our aim was to test the hypothesis that
targeting HDAC5 could be a suitable strategy to treat
cognitive decline linked to AD pathogenesis. In con-
trast to this hypothesis, our data shows that HDAC5
is essential for memory consolidation in mice and that
loss of HDAC5 does not improve cognition in a mouse
model for AD. This data provides two important find-
ings. First, future HDAC inhibitors for the treatment of
AD should avoid targeting HDAC5 and second, strate-
gies that increase, rather than inhibit HDAC5 could
serve as novel therapeutic approaches.
MATERIALS AND METHODS
Animals
Mice were housed under standard conditions with
free access to food and water ab libitum. All experi-
ments were approved by the Animal Committee of the
state of Lower Saxony, Germany. The genetic back-
ground of all mice was C57BL/6J. The APP/PS1-21
mouse model used for our experiments, a double trans-
genic Thy1-APP (KM670/671NL) and Thy1-PS1
(L166 P), was first described by Radde et al. [20].
HDAC5 mutant mice were originally described by
McKinsey et al. [21].
Behavioral analysis
Behavior testing was performed as described previ-
ously [8, 22, 23]. In brief, mice were single housed and
habituated to the testing room 1 week before behav-
ior experiments. Tests were conducted when the mice
were 10-months of age. Mice were subjected to a bat-
tery of behavioral tests: open field, elevated-plus maze,
context/tone fear conditioning, and Morris water maze.
Unless otherwise indicated, the results present pooled
data from male and female mice in case two way
ANOVA showed no gender-related difference among
groups. For the open field test, mice were placed in the
center of a plastic arena (length 1 m; width 1 m; side
walls 20 cm height) for 5 min. The explorative behav-
ior was recorded by a camera and analyzed using the
VideoMot2 software (TSE Systems). For elevated plus
maze analysis, mice were placed in the center region of
the elevated maze facing the open arm. The behavior
was recorded for 5 min using the VideoMot2 system
(version 5.72; TSE systems). Fear conditioning train-
ing was performed using the TSE fear conditioning
system. The procedure consisted of exposing mice to
the conditioning context (3 min) followed by a sin-
gle electric footshock (0.7 mA, constant current, 2 s).
Afterward, mice were left in the conditioning box for
15 s before being returned to their home cage. Freez-
ing was analyzed 24 h later during re-exposure to the
conditioning context. For tone-dependent fear condi-
tioning, a tone (10 kHz, 75 db) was presented for 30 s
prior to the footshock and tone-dependent memory was
tested by placing the mice into a novel context for 1 min
followed by 3 min exposure to the conditioning tone.
Water maze training was performed in a circular tank
(diameter 1.2 m) filled with opaque water. A platform
(11 × 11 cm) was submerged below the water’s sur-
face in the center of the target quadrant. The swimming
path of the mice was recorded by a video camera and
analyzed by the Videomot 2 software (TSE). For each
training session, the mice were placed into the maze
subsequently from four random points of the tank and
were allowed to search for the platform for 60 s. If the
mice did not find the platform within 60 s, they were
gently guided to it. Mice were allowed to remain on the
platform for 15 s. On day 10, mice were subjected to
one memory test (probe trial) 24 h after the last train-
ing session. During the probe test the platform was
removed from the tank and the mice were allowed to
swim in the maze for 60 s.
Quantitative real-time PCR (qPCR)
Total RNA was isolated using the TRI reagent
(Sigma-Aldrich, Steinheim Germany) according to
the manufacturer’s instructions. RNA was dissolved
in 30l ddH2O. qPCR was performed using a
Roche 480 Light Cycler (Roche, Mannheim, Ger-
many). cDNA was synthesized from 1g of total
RNA using the iScript cDNA Synthesis Kit (BIO-
RAD, Hercules, USA) according to the manufacturer’s
instructions. Expression of individual genes was
analyzed using the Roche Universal Probe Library
(UPL). The housekeeping gene hypoxanthine phos-
phoribosyltransferase 1 (Hprt1) was chosen as an
internal reference for normalization of gene expres-
sion. To detect the human App transgene we used
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the following primers and UPL probes: Hprt1-L 5′-
TCCTCCTCAGACCGCTTTT-3′ (UPL #95); Hprt1-
R 5′-CCTGGTTCATCATCGCTAATC-3’ (UPL #95);
hApp-L 5′-CCTGGTGATCCATGTCAGAA-3′ (UPL
#11); hApp-R 5′-AAACACTGCCAAGGTGTCAA-3′
(UPL #11).
Immunoblot analysis
Proteins were isolated using the TRI reagent (Sigma-
Aldrich, Steinheim, Germany) according to the
manufacturer’s instructions. Proteins were dissolved
in 3 M urea in 0.01 M PBS using an ultrasonic homog-
enizer for 10 s, at 8 cycles and 85% power (Bandelin
Electronic, Berlin, Germany). For immunoblot analy-
sis, protein lysates were mixed with Laemmli loading
buffer, heated at 98◦C for 3 min, centrifuged shortly,
and stored at 4◦C. Individual proteins were resolved
on a 12% SDS-polyacrylamide gel by electrophore-
sis (Bio-Rad, Germany) at 120 V. The PageRuler
Prestained Protein Ladder (Fermentas, Germany) was
taken as molecular weight standard. After resolution,
the proteins were transferred to a nitrocellulose mem-
brane at 60 V for 16 h on ice at 4◦C. The membrane
was washed in 0.01 M PBS at room temperature (RT)
and incubated in 5% milk prepared in 0.01 M PBS at
RT for 1 h to block non-specific sites. Primary anti-
body dissolved in 0.5% milk in 0.01 M PBS was used
to probe the membrane at 4◦C overnight on a shaker.
The antibodies used were: mouse A17–24 (4G8)
(1 : 1000, Convance) and anti-Actin (1 : 1000, Santa
Cruz). IRDye 800CW or 680CW conjugated poly-
clonal anti-mouse or anti-rabbit IgG cross-adsorbed
secondary antibodies (1 : 15000, LICOR) were dis-
solved in 0.5% milk in 0.01 M PBS, added on the
membrane and incubated for 30 min at RT on a shaker
in the dark. Unspecific binding was washed using
0.01 M PBS thrice for 10 min. Detection was per-
formed using the Odyssey IR Scanner.
Immunohistochemistry
Immunostaining and quantification was performed
as described previously [13, 23] and analyzed
using a Leica SP2 confocal microscope. The fol-
lowing antibodies were commercially purchased
and used in the mentioned concentrations: NeuN
(1 : 1000; Chemicon); Map2 (1 : 1000, Synaptic
Systems); synaptophysin (Svp38) (1 : 1000, Sigma-
Aldrich); synaptoporin (1 : 1000, Synaptic Systems);
and A17–24 (4G8) (1 : 1000, Convance).
Statistical analysis
The data was analyzed by unpaired student’s t-test
and two-way ANOVA (ANalysis Of VAriance) when
appropriate. Bonferroni post-hoc test was used with
two-way ANOVA analysis. Errors are displayed as
standard error of the mean (SEM). Graphs were gen-
erated using GraphPad Prism.
RESULTS
The present study was designed to address two
questions: 1) to analyze the role of HDAC5 in memory
consolidation; and 2) to investigate if HDAC5 would
affect disease pathology and cognitive function in a
mouse model for AD. Thus we set up breeding among
APP/PS1-21 mice that exhibit aggressive amyloid-
plaques pathology [20] and mice that lack HDAC5
[24] to obtain 4 experimental groups: wild type control
mice (WT), HDAC5 knockout mice (HDAC5 –/–),
APP/PS1-21 mice (APP), and APP/PS1-21 mice
that lack HDAC5 (APP-HDAC5 –/–). Since robust
memory impairment can be detected in 8–12 month old
APP mice [13, 20], we decided to perform molecular
and behavioral analysis of all groups in 10-month old
animals. We measured spatial memory performance
using the hippocampus-dependent Morris water
maze test. All groups except the APP-HDAC5 –/–
group improved in their ability to find the hidden
platform throughout the training days (Fig. 1A) and
showed a significantly reduced escape latency when
comparing the last versus the first day of training
(Fig. 1B). This effect was neither due to alterations
in the swimming distance nor the swimming speed
that was similar among groups (Fig. 1C, D). Also,
no sign of thigmotaxis was observed in any of the
groups. When the probe test was performed 24 h after
the last day of training, only WT mice, but none of
the other groups, showed a significant preference
for the target quadrant (Fig. 1E). When the number
of platform crossings, a sensitive measure of spatial
memory was analyzed, we observed that all groups
were impaired when compared to WT mice (Fig. 1F).
Although the interaction among the two variables
APP and HDAC5 was not significant (Interaction:
F(1,42) = 2.12, p = 0.15), the main effect of HDAC5
–/– on platform crossings was significant (Hdact5
–/–: F(1,42) = 11.96, p < 0.01). Bonferroni post-hoc
test indicated that in mice without APP pathology,
lack of HDAC5 had a significant effect (WT versus
HDAC5 –/–, p < 0.01). The main effect of APP
pathology on platform crossings was borderline
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Fig. 1. Impaired spatial memory formation in HDAC5 –/– mice. A) When compared to the WT group, the escape latency throughout the
training was significantly impaired in 10-month-old HDAC5 –/–, APP, and APP-HDAC5 –/– mice using two-way ANOVA with repeated
measurements. For clarification, the pooled data comparing all 4 groups is shown along with the graphs depicting individual comparisons to
the WT control group. WT versus HDAC5 –/–: (Interaction (Genotype & Time): F(8,128) = 1.77, p = 0.08; Genotype: F(1,128) = 6.04, p < 0.05;
Time: F(8,128) = 28.91, p < 0.0001}; WT versus APP: (Interaction (Genotype & Time): F(8,176) = 0.84, p = 0.56; Genotype: F(1,176) = 11.88,
p < 0.01; Time: F(8,176) = 45.43, p < 0.0001}; WT versus APP-HDAC5 –/–: (Interaction (Genotype & Time): F(8,176) = 2.02, p < 0.05; Geno-
type: F(1,176) = 15.71, p < 0.001; Time: F(8,176) = 32.98, p < 0.0001}. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 versus WT; &p < 0.05 versus APP
using student’s t-test. B) Escape latency was compared on day 1 versus the last day (day 9) of training. Day 1: (Interaction: F(1,40) = 0.00, p = 0.99;
Hdact5–/–: F(1,40) = 0.13,p = 0.72; APP: F(1,40) = 0.59,p = 0.44); Day 9: (Interaction: F(1,40) = 0.13,p = 0.72;Hdact5–/–: F(1,40) = 7.28,p < 0.05;
APP: F(1,40) = 4.89, p < 0.05). While all groups improved in their ability to find the hidden platform, APP-HDAC5 –/– mice performed signif-
icantly worse than the other groups (∗p < 0.05 using student’s t-test). C) Swimming speed during the days of training was similar among groups
(Interaction: F(1,53) = 0.00, p = 0.94; Hdact5 –/–: F(1,53) = 0.51, p = 0.47; APP: F(1,53) = 0.13, p = 0.72). D) Swimming speed during the days of
training was similar among groups (Interaction: F(1,53) = 0.00, p = 0.95; Hdact5 –/–: F(1,53) = 0.51, p = 0.47; APP: F(1,53) = 0.12, p = 0.72). E)
After 9 days of training, mice were subjected to a probe trial. The time spent in the target quadrant was significantly impaired in HDAC5 –/–
and APP-HDAC5 –/– mice when compared to the WT control group (∗p < 0.05 using student’s t-test). Target preference in APP mice was not
significantly different to the WT group (p = 0.10), however, APP mice failed to discriminate between the target quadrant (T) and quadrant 3 (Q3)
indicating that the APP mice also display impaired spatial memory consolidation (Interaction: F(1,40) = 0.35, p = 0.55; Hdact5 –/–: F(1,40) = 4.54,
p < 0.05; APP: F(1,40) = 0.13, p = 0.71). ∗p < 0.05 versus WT using student’s t-test. F) The number of target crossings during the probe test was
significantly reduced in HDAC5 –/–, APP, and APP-HDAC5 –/– mice when compared to the WT group. Interaction: F(1,42)=2.12, p = 0.15;
Hdact5 –/–: F(1,42) = 11.96, p < 0.01; APP: F(1,42) = 3.36, p = 0.07. ∗p < 0.05 and ∗∗p < 0.001 versus WT; &p < 0.05 versus APP using student’s
t-test. T, target quadrant, Q1, quadrant 1; Q2, quadrant 2; Q3, quadrant 3; Q4, quadrant 4. n = 16–20/group. Error bars indicate SEM.
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Fig. 2. Loss of HDAC5 impairs associative memory consolidation. A) Total distance covered in the novel context (Interaction: F(1,32) = 0.06,
p = 0.80; Hdact5 –/–: F(1,32) = 0.08, p = 0.77; APP: F(1,32) = 0.09, p = 0.77). B) Response to electric shock (ES) shown by maximum velocity
before (pre-ES) and after the ES. Pre-ES (Interaction: F(1,32) = 0.19, p = 0.66; Hdact5 –/–: F(1,32) = 0.00, p = 0.95; APP: F(1,32) = 0.01, p = 0.94);
ES (Interaction: F(1,32) = 0.02, p = 0.90; Hdact5 –/–: F(1,32) = 0.00, p = 1.00; APP: F(1,32) = 0.04, p = 0.84). C) Basal freezing behavior shown
upon context exposure (Interaction: F(1,32) = 0.12, p = 0.72; Hdact5 –/–: F(1,32) = 0.01, p = 0.94; APP: F(1,32) = 0.01, p = 0.94). D) Freezing
behavior in the contextual memory test was significantly impaired in HDAC5 –/–, APP, and APP-HDAC5 –/– mice when compared to
the WT control group (Interaction: F(1,37) = 16.65, p < 0.001; Hdact5 –/–: F(1,37) = 29.12, p < 0.001; APP: F(1,37) = 6.64, p < 0.05). Bonferroni
post-hoc test indicated that in mice lacking APP pathology, the lack of HDAC5 –/– had a significant effect (p < 0.001), but not significance
was observed in the APP background. &p < 0.05 versus WT using student’s t-test. E) Freezing behavior in the tone-dependent memory test
was significantly reduced in HDAC5 –/– and APP-HDAC5 –/– but not in APP mice when compared to WT control mice (Interaction:
F(1,37) = 1.37, p = 0.43; Hdact5 –/–: F(1,37) = 15.53, p < 0.001; APP: F(1,37) = 0.46, p = 0.50). Bonferroni post-hoc test indicated that not only
in mice lacking APP pathology, the lack of HDAC5 –/– had a significant effect (∗∗p < 0.01), but this effect was also significant in the APP
background (∗p < 0.01). &p < 0.05 versus APP using student’s t-test. n = 8–12/group. Error bars indicate SEM.
non-significant (APP: F(1,42) = 3.36, p = 0.07).
Interestingly, in direct comparison to the APP group,
the number of platform crossings was significantly
impaired in the APP-HDAC5 –/– group (Fig. 1F).
In conclusion, this data indicates that spatial memory
performance is impaired in HDAC5–/– mice, an effect
that is slightly enhanced in the context of amyloid
pathology.
We also analyzed associative memory employ-
ing the context and tone-dependent Pavlovian
fear-conditioning paradigm. The distance traveled
(Fig. 2A), the activity, and the response to electric
foot-shock (Fig. 2B) during the training were compa-
rable among groups. Moreover, only baseline freezing
behavior was observed in all groups during the training
procedure (Fig. 2C) suggesting that sensory processing
was not affected. When re-exposed to the condition-
ing context 24 h after the training, APP mice showed
significantly reduced freezing behavior indicative of
impaired hippocampus-dependent associative learn-
ing (Fig. 2D). Freezing behavior was also impaired
in HDAC5 –/– mice when compared to the WT con-
trol group (Fig. 2D). A similar finding was observed
in the APP-HDAC5 –/– group (Fig. 2D). However,
APP-HDAC5 –/– mice did not significantly differ
from either APP or HDAC5 –/– mice (Fig. 2D). Tone-
dependent memory that requires proper function of the
amygdala was assessed in the same groups of mice.
APP mice showed a trend for impaired memory con-
solidation that, however, was not statistical significant
when compared to the WT control group (Fig. 2E).
In contrast, HDAC5 –/– mice showed reduced freez-
ing behavior when compared to the WT control group
suggesting that tone-dependent memory consolidation
is disturbed in HDAC5 –/– mice (Fig. 2E). In line
with this finding, APP-HDAC5 –/– mice displayed
impaired freezing behavior when compared to the WT
control group and the APP group. Freezing behavior
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Fig. 3. Basal anxiety and explorative behavior in HDAC5 –/– mice. A) Basal anxiety assessed via the open field test was not altered among groups.
Center (Interaction: F(1,49) = 0.11, p = 0.74; Hdact5 –/–: F(1,49) = 0.01, p = 0.90; APP: F(1,49) = 0.00, p = 0.95); Border (Interaction: F(1,51) = 0.01,
p = 0.94; Hdact5 –/–: F(1,51) = 0.09, p = 0.76; APP: F(1,51) = 0.06, p = 0.81). B) Explorative behavior was similar among WT, HDAC5 –/–, and
APP mice. APP-HDAC5 –/– mice displayed enhanced activity when compared to the APP group (Interaction: F(1,49) = 1.98, p = 0.16;
Hdact5 –/–: F(1,49) = 3.67, p = 0.06; APP: F(1,49) = 0.5989, p = 0.44). ∗p < 0.05 using Bonferroni post-hoc test. C) When exposed to the elevated
plus maze test, all four groups of mice spent similar times in the center, the closed or the open arms of the maze confirming that basal anxiety in
not affected. Center (Interaction: F(1,40) = 0.43, p = 0.51; Hdact5 –/–: F(1,40) = 0.05, p = 0.82; APP: F(1,40) = 0.03, p = 0.85); Closed (Interaction:
F(1,44) = 0.21, p = 0.64; Hdact5 –/–: F(1,44) = 0.19, p = 0.66; APP: F(1,44) = 0.73, p = 0.39); Open (Interaction: F(1,47) = 0.93, p = 0.34; Hdact5
–/–: F(1,47) = 0.03, p = 0.86; APP: F(1,47) = 0.01, p = 0.93). n = 15–18/group. Error bars indicate SEM.
among HDAC5 –/– and APP-HDAC5 –/– mice was
not significantly different (Fig. 2E). In conclusion, this
data indicates that HDAC5 plays a role in the consoli-
dation of contextual and tone-dependent fear memories
but has no impact on associative memory function in
APP mice.
We also assessed basal anxiety behavior using the
open field and the elevated plus maze tests. No sig-
nificant difference among groups was observed when
the time spent in the center versus the border of the
open field arena was analyzed, which presents a com-
mon measure of basal anxiety (Fig. 3A). Interestingly,
the total distance traveled during the test period was
increased in APP-HDAC5 –/– mice when compared
to APP mice (Fig. 3B). Although there was no main
effect of amyloid pathology or HDAC5 –/–, the main
effect of HDAC5 –/– was borderline non-significant
(F(1,49) = 3.670, p = 0.06). Nonetheless, Bonferroni
post-hoc tests indicated that in mice with APP pathol-
ogy, the lack of HDAC5 had a significant effect (WT
versus HDAC5 –/–, ∗p < 0.05) on the distance traveled
in the open field. Basal anxiety was also analyzed in
the elevated plus maze test. No difference was detected
among groups (Fig. 3C). In sum, this data indicates that
HDAC5 does not affect basal anxiety levels.
Finally, we analyzed amyloid pathology and hip-
pocampal integrity. First we confirmed that the
expression of the human App (hApp) transgene and the
levels of the corresponding protein were not affected
in HDAC5 –/– mice (Fig. 4A, B).
Next, we measured A-plaque load in the hip-
pocampal region (Fig. 4C, E) and the brainstem
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Fig. 4. Loss of HDAC5 does not affect amyloid pathology. Lack of HDAC5 does not affect either human App (hApp) transgene (A) or protein
expressions (B) in the mice showing APP pathology. Representative confocal microscopy images showing A plaque load in the hippocampus
(C) and the brain stem (D) of APP and APP-HDAC5 –/– mice. Quantification of plaque load in hippocampus (E) and brainstem (F) revealed
no significant difference between APP and APP-HDAC5 –/– mice. A.U., arbitrary units, n = 7–10/group. Error bars indicate SEM.
(Fig. 4D, F) of APP and APP-HDAC5 –/– mice.
Densiometric analysis of 4G8 staining revealed no
significant differences among groups (Fig. 4). Since
WT and HDAC5 –/– mice display no amyloid pathol-
ogy, these groups are not shown. We also analyzed
NeuN, MAP2, synaptophsyin-38, and synaptoprorin
immunoreactivity in the hippocampus, four well-
established markers for neuronal integrity [8, 22]. No
difference was observed among groups (Fig. 5).
DISCUSSION
Deregulation of epigenetic processes such as
histone-acetylation has been observed in neuropsychi-
atric and neurodegenerative diseases [2, 25]. In line
with this, a growing body of literature suggests HDACs
as promising drug targets to treat cognitive dysfunction
in AD [6–9, 11, 13, 26]. Understand the neurobiology
of individual HDAC proteins and their role in cognitive
processes and the pathogenesis of neurodegenerative
diseases including AD is therefore a vital step to
develop more selective HDAC inhibitors and eventu-
ally translate these findings into clinical application.
In this study we investigated the contribution of
HDAC5 to learning and memory processes and the
pathogenesis of AD in a rodent model. To our knowl-
edge, this is the first study to address these questions.
Our data shows that loss of HDAC5 leads to impaired
spatial and associative memory function in mice.
Although HDAC5 –/– mice show normal explorative
behavior and display no deficits in motor function
and basal anxiety, we cannot exclude the impact of
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Fig. 5. Loss of HDAC5 does not cause overt changes in hippocampal integrity. A) Representative images showing immunoreactivity for NeuN,
Map2, synaptophysin-38, and synaptoporin protein levels in the hippocampal formation of WT mice. Scale bar: 100m. B) Quantification of
NeuN, Map2, synaptophysin-38 (Svp38), and synaptoporin immunoreactivity revealed no differences among groups. NeuN-dentate gyrus: Inter-
action: F(1,27) = 0.00,p = 0.98;Hdact5–/–: F(1,27) = 0.08,p = 0.78; APP: F(1,27) = 0.01,p = 0.92); NeuN-CA1: Interaction: F(1,35) = 1.01,p = 0.32;
Hdact5 –/–: F(1,35) = 1.08, p = 0.30; APP: F(1,35) = 0.93, p = 0.34); NeuN-CA3: Interaction: F(1,34) = 0.00, p = 0.96; Hdact5 –/–: F(1,34) = 0.08,
p = 0.77; APP: F(1,34) = 0.02, p = 0.89); Map2: Interaction: F(1,29) = 0.18, p = 0.67; Hdact5 –/–: F(1,29) = 0.55, p = 0.46; APP: F(1,29) = 0.40,
p = 0.53); Svp38: Interaction: F(1,28) = 0.17, p = 0.68; Hdact5 –/–: F(1,28) = 0.69, p = 0.41; APP: F(1,28) = 0.10, p = 0.74); Synaptoporin: Inter-
action: F(1,33) = 1.85, p = 0.18; Hdact5 –/–: F(1,33) = 1.38, p = 0.24; APP: F(1,33) = 0.06, p = 0.80); rad, stratum radiatum; luc, stratum lucidum;
CA1, CA1 pyramidal layer; CA3, CA3 pyramidal layer; DG, dentate gyrus; A.U., arbitrary units. n = 8/group Error bars indicate SEM.
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developmental processes on the observed phenotypes.
Since, previous studies have demonstrated that admin-
istration of pan-HDAC inhibitors facilitate these types
of memories [14, 27–29], our data strongly supports
the view that inhibition of HDAC5 is not responsi-
ble for this effect. In contrary, our data suggest that
inhibition of HDAC5 would be detrimental. In this con-
text it is interesting to mention that previous findings
implicated HDAC5 with cocaine addiction, an extreme
form of synaptic plasticity and learning behavior [18],
suggesting a more general role for HDAC5 in mem-
ory consolidation. In contrast to other HDACs such as
HDAC2 that was shown to act a constraint of memory
consolidation [14], our data indicates that HDAC5 is
essential for memory function. While the underlying
mechanisms remain to be elucidated, it is interesting
to note that HDAC5 has been implicated with histone-
deacetylation [17] and deacetylation of non-histone
proteins such as MEF2 which regulates synaptic plas-
ticity [16, 30]. In line with the observation that HDAC5
is essential for memory formation, loss of HDAC5 did
not improve spatial and associative memory function in
a mouse model for AD. Previous studies have shown
that HDAC inhibitors improve cognitive function in
AD mouse models [1, 6–9, 11, 13]. Our data strongly
suggest that this effect is independent of HDAC5 inhi-
bition. In fact that there was a trend for further impaired
memory function in HDAC5 –/– mice when compared
to APP mice suggesting that targeting HDAC5 should
be avoided when developing novel HDAC inhibitors.
In general our data support the view that class I HDACs
might be better targets to treat memory dysfunction [7,
14], while class II HDACs, such as HDAC5 that might
have a broader role on various cellular mechanisms [1,
31], would not be bona ﬁde drug targets.
In conclusion, our study adds important knowledge
to the fast growing research area investigating the role
of HDACs as drug targets to treat AD. Recent data
suggested that HDAC2 [14, 15], HDAC3 [32], and
also HDAC6 [33] might be suitable drug targets to
treat cognitive decline. In contrast, targeting HDAC1,
which is essential to regulate fear extinction in mice
[34], appears less promising. Our data now clearly
demonstrates that targeting HDAC5 should be avoided
in future drug development programs.
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